Among the various genetic alterations implicated in AML, ten-eleven translocation 2 (TET2) mutations have garnered attention due to its high prevalence in myeloid malignancies and its impact on DNA demethylation and epigenetic regulation (8, 9). This evidence concerns the gene TET2 and myeloid neoplasm.